AAP
NVCT icon

Arax Advisory Partners’s Nuvectis Pharma NVCT Stock Holding History

Arax Advisory Partners’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.6K Buy
+795
New +$8.9K ﹤0.01% 4156
2025
Q4 		– Sell
-38
Closed -$229 – 4398
2025
Q3 		$229 Buy
+38
New +$261 ﹤0.01% 3437

Other funds holding NVCT

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $193M AUM 233.09% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return

Arax Advisory Partners's NVCT Position: Q2 2026 in Review

Arax Advisory Partners opened a new position in Nuvectis Pharma (NVCT) in Q2 2026: 795 shares worth $14.6K. The stake represents ﹤0.01% of the portfolio and ranks #4156 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in NVCT as recently as Q3 2025.

Arax Advisory Partners first reported a position in NVCT in Q3 2025 and has held it in 2 quarters since. 83 funds tracked by Wall St. Rank hold NVCT as of Q2 2026.

  • Arax Advisory Partners held 795 shares of Nuvectis Pharma worth $14.6K as of Q2 2026.
  • Nuvectis Pharma was a new Arax Advisory Partners position in Q2 2026.
  • Nuvectis Pharma made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #4156 holding.
  • Arax Advisory Partners first reported a position in Nuvectis Pharma in Q3 2025 and has held it in 2 quarters since.
  • 83 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.